Stocktoria
Celltrion, Inc. 068270.KS
KR · Korea Exchange · XKRX · stock · Healthcare · website
Celltrion, Inc. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | ₩4.16T | ₩3.56T | ₩2.18T | ₩2.28T |
| Gross profit | ₩2.47T | ₩1.68T | ₩1.05T | ₩1.03T |
| R&D expense | ₩210.7B | ₩199.7B | ₩161.1B | ₩139.7B |
| SG&A expense | ₩554.6B | ₩456.9B | ₩107.9B | ₩112.6B |
| Operating income | ₩1.16T | ₩492.0B | ₩651.5B | ₩647.2B |
| Interest expense | ₩75.5B | ₩75.6B | ₩9.7B | ₩7.5B |
| Income tax | ₩122.2B | ₩157.2B | ₩131.4B | ₩94.8B |
| Net income | ₩1.03T | ₩422.7B | ₩535.6B | ₩537.8B |
| EPS (diluted) | ₩4438.10 | ₩1717.95 | ₩3273.16 | ₩3258.33 |
| Operating cash flow | ₩646.1B | ₩901.9B | ₩537.2B | ₩863.5M |
| Free cash flow | ₩314.3B | ₩568.3B | ₩183.4B | -₩311.1B |
| Cash & equivalents | ₩1.12T | ₩996.4B | ₩564.6B | ₩551.2B |
| Inventory | ₩2.80T | ₩2.77T | ₩3.04T | ₩616.4B |
| Goodwill | ₩11.88T | ₩11.91T | ₩11.43T | ₩35.2B |
| Total assets | ₩22.33T | ₩21.06T | ₩19.96T | ₩5.89T |
| Total debt | ₩3.73T | ₩2.19T | ₩1.89T | ₩792.3B |
| Total liabilities | ₩4.98T | ₩3.48T | ₩2.83T | ₩1.62T |
| Shareholders' equity | ₩17.21T | ₩17.44T | ₩16.98T | ₩4.14T |
| Share buybacks | ₩908.4B | ₩438.8B | ₩918.8B | ₩280.5B |
Growth · year-over-year · Revenue CAGR 22.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +17.0% | +63.4% | -4.7% | — |
| Net income growth | +143.6% | -21.1% | -0.4% | — |
| EPS growth | +158.3% | -47.5% | +0.5% | — |
| Free cash flow growth | -44.7% | +209.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · KR · as of 2025-12-31. Figures in KRW. Facts plus Stocktoria's own computed scores — not investment advice.